D’Amico Risk Categories
Dear OncoLink "Ask The Experts,"
Can you describe the D'Amico risk categories and how they relate to prognosis ?
Richard Whittington, MD, Associate Professor of Radiation Oncology at the University of Pennsylvania School of Medicine, responds:
Dr. Anthony D'Amico has shown that it is possible to estimate the biologic aggressiveness of prostate cancers by grouping them into different risk categories, which in turn reflect the risk of cancer growth and spread. When an urologist does a prostate biopsy, he systematically samples the gland from 6 to 12 – and sometimes up to 24 – different areas. The number of involved areas out of the total number sampled is a term called “percent positive biopsies (or cores)”, and indicates how much of the prostate gland is involved with cancer. For example, Dr. D’Amico has found that a tumor that only involves a small percentage of cores can be classified as low risk, whereas a high percentage of positive cores portends a worse prognosis.
Below is the overall risk stratification of this system:
PSA < 10ng/ml and Gleason < 6 and
The percentage of involved cores is < 50% or
Intermediate risk with only 1 positive core
Gleason score of 7 or PSA of 10-20
Low risk with > 50% of positive cores or
High risk and only 1 positive core
Gleason > 8 or PSA > 20 and more than 1 positive core
Or intermediate risk and more than 50% positive cores
When there is a conflict in the Gleason score and PSA risk group, the worse factor wins and determines the risk category assignment. For example, a patient with a low Gleason Score of 6 combined with a PSA of 25 ng/ml is considered high risk. The exception to this would be, say, if there is only one positive core out of all of the ones sampled, in which case the risk category goes down to intermediate risk.
OncoLink is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through OncoLink should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem or have questions or concerns about the medication that you have been prescribed, you should consult your health care provider.
Information Provided By: www.oncolink.org | © 2016 Trustees of The University of Pennsylvania